Literature DB >> 9288970

Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.

F X Gomis-Rüth1, K Maskos, M Betz, A Bergner, R Huber, K Suzuki, N Yoshida, H Nagase, K Brew, G P Bourenkov, H Bartunik, W Bode.   

Abstract

Matrix metalloproteinases (MMPs) are zinc endopeptidases that are required for the degradation of extracellular matrix components during normal embryo development, morphogenesis and tissue remodelling. Their proteolytic activities are precisely regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs). Disruption of this balance results in diseases such as arthritis, atherosclerosis, tumour growth and metastasis. Here we report the crystal structure of an MMP-TIMP complex formed between the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1. TIMP-1, a 184-residue protein, has the shape of an elongated, contiguous wedge. With its long edge, consisting of five different chain regions, it occupies the entire length of the active-site cleft of MMP-3. The central disulphide-linked segments Cys 1-Thr 2-Cys 3-Val 4 and Ser 68-Val 69 bind to either side of the catalytic zinc. Cys 1 bidentally coordinates this zinc, and the Thr-2 side chain extends into the large specificity pocket of MMP-3. This unusual architecture of the interface between MMP-3 and TIMP-1 suggests new possibilities for designing TIMP variants and synthetic MMP inhibitors with potential therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288970     DOI: 10.1038/37995

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  128 in total

1.  The NTR module: domains of netrins, secreted frizzled related proteins, and type I procollagen C-proteinase enhancer protein are homologous with tissue inhibitors of metalloproteases.

Authors:  L Bányai; L Patthy
Journal:  Protein Sci       Date:  1999-08       Impact factor: 6.725

Review 2.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 3.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 4.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

Review 5.  Evolutionary families of peptidase inhibitors.

Authors:  Neil D Rawlings; Dominic P Tolle; Alan J Barrett
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

6.  Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: a new frontier in TIMP engineering.

Authors:  Meng-Huee Lee; Klaus Maskos; Vera Knäuper; Philippa Dodds; Gillian Murphy
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

Review 7.  Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology.

Authors:  Mahavir Singh; Suresh C Tyagi
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

8.  Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.

Authors:  Sergio Manzetti
Journal:  J Mol Model       Date:  2003-08-29       Impact factor: 1.810

Review 9.  Digestive Inflammation: Role of Proteolytic Dysregulation.

Authors:  Vincent Mariaule; Aicha Kriaa; Souha Soussou; Soufien Rhimi; Houda Boudaya; Juan Hernandez; Emmanuelle Maguin; Adam Lesner; Moez Rhimi
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

10.  Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.

Authors:  C Fernandez-Catalan; W Bode; R Huber; D Turk; J J Calvete; A Lichte; H Tschesche; K Maskos
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.